Adding dulaglutide to current kidney and diabetes treatment
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether adding dulaglutide to your current diabetes and kidney treatment can slow down kidney disease. It's designed for people with type 2 diabetes who have chronic kidney problems and are already on two specific medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18 or older).
- You need both type 2 diabetes and chronic kidney disease.
- Your HbA1c (a measure of your average blood sugar) should be between 7.0% and 11%.
- You must have a high level of protein in your urine (a sign of kidney damage).
- Your weight must be in a range that corresponds to a body mass index (BMI) of 21 to 45.
- You must already be taking an SGLT2 inhibitor and finerenone, plus standard blood pressure medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medicine called ganagliflozin can slow down kidney damage in people with type 2 diabetes and chronic kidney disease. If you qualify, you may be able to take part in this study to see if it helps protect your kidneys.
This study tests whether adding a non-steroidal mineralocorticoid antagonist to your current type 2 diabetes and kidney disease medications (SGLT2i and ACEi/ARB) is cost-effective. It may help preserve kidney function and reduce heart risks.
This Phase 2 trial tests whether combining two diabetes medicines—an SGLT2 tablet and a GLP-1 shot (semaglutide)—can improve kidney outcomes and safety in people with a kidney transplant. It may help some recipients, but it also carefully checks for infection risk, diabetes complications, and pregnancy plans.
This study looks at whether a urine test can help doctors choose the right medicines earlier to prevent kidney and heart problems in people with type 2 diabetes. You may join if you have type 2 diabetes but no severe heart failure.
This Phase 2 study tests semaglutide (a diabetes and weight-related medicine) to see if it can slow or improve diabetic kidney disease in people with type 1 diabetes. You may be able to join if you have type 1 diabetes for at least 5 years and ongoing signs of kidney damage measured in urine tests.
This trial looks at whether a medicine called an SGLT2 inhibitor (a type of diabetes drug) can help protect the kidneys and heart in people with chronic kidney disease or type 2 diabetes. If you have either condition, you might be able to join.
Hear when a new T2DM (Type 2 Diabetes Mellitus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.